

Vicky Goh

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3507063/publications.pdf>

Version: 2024-02-01

216
papers

14,062
citations

25034
57
h-index

22832
112
g-index

223
all docs

223
docs citations

223
times ranked

16043
citing authors

#	ARTICLE	IF	CITATIONS
1	The impact of Human Papilloma Virus status on the prediction of head and neck cancer chemoradiotherapy outcomes using the pre-treatment apparent diffusion coefficient. British Journal of Radiology, 2022, 95, 20210333.	2.2	3
2	Exercise prehabilitation during neoadjuvant chemotherapy may enhance tumour regression in oesophageal cancer: results from a prospective non-randomised trial. British Journal of Sports Medicine, 2022, 56, 402-409.	6.7	25
3	Radiomic Analysis of Tumour Heterogeneity Using MRI in Head and Neck Cancer Following Chemoradiotherapy: A Feasibility Study. Frontiers in Oncology, 2022, 12, 784693.	2.8	2
4	Correlation between whole skeleton dual energy CT calcium-subtracted attenuation and bone marrow infiltration in multiple myeloma. European Journal of Radiology, 2022, 149, 110223.	2.6	4
5	Radiomic assessment of oesophageal adenocarcinoma: a critical review of 18F-FDG PET/CT, PET/MRI and CT. Insights Into Imaging, 2022, 13, .	3.4	4
6	State-of-the-art imaging in oesophago-gastric cancer. British Journal of Radiology, 2022, 95, .	2.2	0
7	¹⁸ F FDG PET/CT and Novel Molecular Imaging for Directing Immunotherapy in Cancer. Radiology, 2022, 304, 246-264.	7.3	14
8	Distortion-free 3D diffusion imaging of the prostate using a multishot diffusion-prepared phase-cycled acquisition and dictionary matching. Magnetic Resonance in Medicine, 2021, 85, 1441-1454.	3.0	1
9	Arterial Spin Labeled Perfusion MRI for Assessing Antiangiogenic Therapy: A Step Forward or Just More Spin?. Radiology, 2021, 298, 341-342.	7.3	0
10	Comparison of the diagnostic performance and impact on management of 18F-FDG PET/CT and whole-body MRI in multiple myeloma. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 2558-2565.	6.4	13
11	A Multi-Channel Uncertainty-Aware Multi-Resolution Network for MR to CT Synthesis. Applied Sciences (Switzerland), 2021, 11, 1667.	2.5	7
12	Systematic review of research design and reporting of imaging studies applying convolutional neural networks for radiological cancer diagnosis. European Radiology, 2021, 31, 7969-7983.	4.5	14
13	Correlations between DW-MRI and 18 F-FDG PET / CT parameters in head and neck squamous cell carcinoma following definitive chemo-radiotherapy. Cancer Reports, 2021, 4, e1360.	1.4	4
14	Occupational radiation exposure in doctors: an analysis of exposure rates over 25 years. British Journal of Radiology, 2021, 94, 20210602.	2.2	5
15	Apparent diffusion coefficient agreement and reliability using different region of interest methods for the evaluation of head and neck cancer post chemo-radiotherapy. Dentomaxillofacial Radiology, 2021, 50, 20200579.	2.7	6
16	Integrated slice-specific dynamic shimming for whole-body diffusion-weighted MR imaging at 1.5T. Magnetic Resonance Materials in Physics, Biology, and Medicine, 2021, 34, 513-521.	2.0	4
17	Sparse Regression in Cancer Genomics: Comparing Variable Selection and Predictions in Real World Data. Cancer Informatics, 2021, 20, 117693512110562.	1.9	2
18	Initial experience in staging primary oesophageal/gastro-oesophageal cancer with 18F-FDG PET/MRI. European Journal of Hybrid Imaging, 2021, 5, 23.	1.5	7

#	ARTICLE	IF	CITATIONS
19	Radiomic analysis for response assessment in advanced head and neck cancers, a distant dream or an inevitable reality? A systematic review of the current level of evidence. British Journal of Radiology, 2020, 93, 20190496.	2.2	19
20	Heterogeneity in tumours: Validating the use of radiomic features on 18F-FDG PET/CT scans of lung cancer patients as a prognostic tool. Radiotherapy and Oncology, 2020, 144, 72-78.	0.6	35
21	Assessing Radiology Research on Artificial Intelligence: A Brief Guide for Authors, Reviewers, and Readersâ€”From the <i>Radiology</i> Editorial Board. Radiology, 2020, 294, 487-489.	7.3	229
22	Cost-Effectiveness of Immediate Magnetic Resonance Imaging In the Management of Patients With Suspected Scaphoid Fracture: Results From a Randomized Clinical Trial. Value in Health, 2020, 23, 1444-1452.	0.3	9
23	Synthesis and in vivo evaluation of PEG-BPâ€”BaYbF5 nanoparticles for computed tomography imaging and their toxicity. Journal of Materials Chemistry B, 2020, 8, 7723-7732.	5.8	8
24	Predictors of patient preference for either whole body magnetic resonance imaging (WBâ€”MRI) or CT/PETâ€”CT for staging colorectal or lung cancer. Journal of Medical Imaging and Radiation Oncology, 2020, 64, 537-545.	1.8	8
25	A Role for FDG PET Radiomics in Personalized Medicine?. Seminars in Nuclear Medicine, 2020, 50, 532-540.	4.6	12
26	The Image Biomarker Standardization Initiative: Standardized Quantitative Radiomics for High-Throughput Image-based Phenotyping. Radiology, 2020, 295, 328-338.	7.3	1,869
27	Identification of Subtypes of Barrettâ€™s Esophagus and Esophageal Adenocarcinoma Based on DNA Methylation Profiles and Integration of Transcriptome and Genome Data. Gastroenterology, 2020, 158, 1682-1697.e1.	1.3	58
28	Oxygen-enhanced MRI MOLLI T1 mapping during chemoradiotherapy in anal squamous cell carcinoma. Clinical and Translational Radiation Oncology, 2020, 22, 44-49.	1.7	5
29	The Impact of the COVID-19 Pandemic on the Radiology Research Enterprise: Radiology Scientific Expert Panel. Radiology, 2020, 296, E134-E140.	7.3	29
30	Predicting Growth Kinetics in Hereditary Renal Cancer with Diffusion-weighted MRI. Radiology, 2020, 295, 591-592.	7.3	1
31	Molecular Imaging of Bone Metastases and Their Response to Therapy. Journal of Nuclear Medicine, 2020, 61, 799-806.	5.0	37
32	Machine learning to predict early recurrence after oesophageal cancer surgery. British Journal of Surgery, 2020, 107, 1042-1052.	0.3	35
33	Management of chronic headache with referral from primary care to direct access to MRI compared with Neurology services: an observational prospective study in London. BMJ Open, 2020, 10, e036097.	1.9	0
34	Management of chronic headache with referral from primary care to direct access to MRI compared with Neurology services: an observational prospective study in London. BMJ Open, 2020, 10, e036097.	1.9	4
35	Is Response Assessment of Breast Cancer Bone Metastases Better with Measurement of ¹⁸ F-Fluoride Metabolic Flux Than with Measurement of ¹⁸ F-Fluoride PET/CT SUV?. Journal of Nuclear Medicine, 2019, 60, 322-327.	5.0	23
36	Radiomics in esophageal and gastric cancer. Abdominal Radiology, 2019, 44, 2048-2058.	2.1	59

#	ARTICLE	IF	CITATIONS
37	Assessment of the Spatial Heterogeneity of Breast Cancers: Associations Between Computed Tomography and Immunohistochemistry. <i>Biomarkers in Cancer</i> , 2019, 11, 1179299X1985151.	3.6	4
38	Automated Triaging of Adult Chest Radiographs with Deep Artificial Neural Networks. <i>Radiology</i> , 2019, 291, 196-202.	7.3	176
39	Early stage anal margin cancer: towards evidence-based management. <i>Colorectal Disease</i> , 2019, 21, 387-391.	1.4	14
40	Non-invasive classification of non-small cell lung cancer: a comparison between random forest models utilising radiomic and semantic features. <i>British Journal of Radiology</i> , 2019, 92, 20190159.	2.2	32
41	What can artificial intelligence teach us about the molecular mechanisms underlying disease?. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2019, 46, 2715-2721.	6.4	15
42	Diagnostic accuracy of whole-body MRI versus standard imaging pathways for metastatic disease in newly diagnosed non-small-cell lung cancer: the prospective Streamline L trial. <i>Lancet Respiratory Medicine</i> , 2019, 7, 523-532.	10.7	50
43	Diagnostic accuracy of whole-body MRI versus standard imaging pathways for metastatic disease in newly diagnosed colorectal cancer: the prospective Streamline C trial. <i>The Lancet Gastroenterology and Hepatology</i> , 2019, 4, 529-537.	8.1	51
44	Loco-regional staging of malignant pleural mesothelioma by integrated 18F-FDG PET/MRI. <i>European Journal of Radiology</i> , 2019, 115, 46-52.	2.6	19
45	Accelerated 3D T ₂ -weighted imaging of the prostate with 1-mm isotropic resolution in less than 3 minutes. <i>Magnetic Resonance in Medicine</i> , 2019, 82, 721-731.	3.0	11
46	Transcriptomic profiling reveals three molecular phenotypes of adenocarcinoma at the gastroesophageal junction. <i>International Journal of Cancer</i> , 2019, 145, 3389-3401.	5.1	17
47	Adaptive statistical iterative reconstruction (ASIR) affects CT radiomics quantification in primary colorectal cancer. <i>European Radiology</i> , 2019, 29, 5227-5235.	4.5	27
48	The National Institute for Health Research: making an impact in imaging research. <i>Clinical Radiology</i> , 2019, 74, 242-246.	1.1	3
49	Exploratory radiomic features from integrated 18F-fluorodeoxyglucose positron emission tomography/magnetic resonance imaging are associated with contemporaneous metastases in oesophageal/gastroesophageal cancer. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2019, 46, 1478-1484.	6.4	17
50	Patient preferences for whole-body MRI or conventional staging pathways in lung and colorectal cancer: a discrete choice experiment. <i>European Radiology</i> , 2019, 29, 3889-3900.	4.5	20
51	MRI heterogeneity analysis for prediction of recurrence and disease free survival in anal cancer. <i>Radiotherapy and Oncology</i> , 2019, 134, 119-126.	0.6	15
52	Prediction of a positive circumferential resection margin at surgery following neoadjuvant chemotherapy for adenocarcinoma of the oesophagus. <i>BJS Open</i> , 2019, 3, 767-776.	1.7	3
53	Measurement of 18F-FDG PET tumor heterogeneity improves early assessment of response to bevacizumab compared with the standard size and uptake metrics in a colorectal cancer model. <i>Nuclear Medicine Communications</i> , 2019, 40, 611-617.	1.1	7
54	Does Measurement of First-Order and Heterogeneity Parameters Improve Response Assessment of Bone Metastases in Breast Cancer Compared to SUVmax in [18F]fluoride and [18F]FDG PET?. <i>Molecular Imaging and Biology</i> , 2019, 21, 781-789.	2.6	11

#	ARTICLE	IF	CITATIONS
55	Learning to detect chest radiographs containing pulmonary lesions using visual attention networks. Medical Image Analysis, 2019, 53, 26-38.	11.6	77
56	Accelerated 3D T ₂ mapping with dictionary-based matching for prostate imaging. Magnetic Resonance in Medicine, 2019, 81, 1795-1805.	3.0	16
57	Prediction of therapy response in bone-predominant metastatic breast cancer: comparison of [18F] fluorodeoxyglucose and [18F]-fluoride PET/CT with whole-body MRI with diffusion-weighted imaging. European Journal of Nuclear Medicine and Molecular Imaging, 2019, 46, 821-830.	6.4	31
58	Whole-body MRI compared with standard pathways for staging metastatic disease in lung and colorectal cancer: the Streamline diagnostic accuracy studies. Health Technology Assessment, 2019, 23, 1-270.	2.8	34
59	Anal Canal. , 2019, , 77-85.		0
60	Reply: Relevance of Measurement Uncertainty for Quantitative Response Assessment of Breast Cancer Bone Metastases with ¹⁸ F-Fluoride. Journal of Nuclear Medicine, 2019, 60, 569.1-569.	5.0	4
61	Characterization of Small Renal Tumors With Magnetic Resonance Elastography. Investigative Radiology, 2018, 53, 344-351.	6.2	14
62	Functional and Hybrid Imaging of Bone Metastases. Journal of Bone and Mineral Research, 2018, 33, 961-972.	2.8	18
63	Imaging α integrin expression in skeletal metastases with 99mTc-maraciclalide single-photon emission computed tomography: detection and therapy response assessment. European Journal of Nuclear Medicine and Molecular Imaging, 2018, 45, 898-903.	6.4	9
64	Rationale and design of the SMaRT trial: A randomised, prospective, parallel, non-blinded, one-centre trial to evaluate the use of magnetic resonance imaging in acute setting in patients presenting with suspected scaphoid fracture. Clinical Trials, 2018, 15, 120-129.	1.6	4
65	Challenges and Promises of PET Radiomics. International Journal of Radiation Oncology Biology Physics, 2018, 102, 1083-1089.	0.8	121
66	Imaging of Tumour Heterogeneity: Functional MR Techniques in Oncology. , 2018, , 131-150.		0
67	Comparison of whole body magnetic resonance imaging (WBMRI) to whole body computed tomography (WBCT) or 18 F-fluorodeoxyglucose positron emission tomography/CT (18 F-FDG PET/CT) in patients with myeloma: Systematic review of diagnostic performance. Critical Reviews in Oncology/Hematology. 2018. 124. 66-72.	4.4	43
68	UK quantitative WB-DWI technical workgroup: consensus meeting recommendations on optimisation, quality control, processing and analysis of quantitative whole-body diffusion-weighted imaging for cancer. British Journal of Radiology, 2018, 91, 20170577.	2.2	70
69	Weight-adapted iodinated contrast media administration in abdomino-pelvic CT: Can image quality be maintained?. Radiography, 2018, 24, 22-27.	2.1	16
70	The economic evidence for advanced imaging in the diagnosis of suspected scaphoid fractures: systematic review of evidence. Journal of Hand Surgery: European Volume, 2018, 43, 642-651.	1.0	11
71	The impact of MRI sequence on tumour staging and gross tumour volume delineation in squamous cell carcinoma of the anal canal. European Radiology, 2018, 28, 1512-1519.	4.5	21
72	Investigating the histopathologic correlates of 18F-FDG PET heterogeneity in non-small-cell lung cancer. Nuclear Medicine Communications, 2018, 39, 1197-1206.	1.1	13

73	Identification of Prognostic Phenotypes of Esophageal Adenocarcinoma in 2 Independent Cohorts. Gastroenterology, 2018, 155, 1720-1728.e4.	1.3	67
74	Novel imaging techniques in staging oesophageal cancer. Bailliere's Best Practice and Research in Clinical Gastroenterology, 2018, 36-37, 17-25.	2.4	29
75	BACCHUS: A randomised non-comparative phase II study of neoadjuvant chemotherapy (NACT) in patients with locally advanced rectal cancer (LARC). Heliyon, 2018, 4, e00804.	3.2	21
76	Added Value of Contrast-Enhanced T1-Weighted and Diffusion-Weighted Sequences for Characterization of Incidental Findings on Whole Body Magnetic Resonance Imaging in Plasma-Cell Disorders. Clinical Lymphoma, Myeloma and Leukemia, 2018, 18, 822-828.	0.4	4
77	National survey of imaging practice for suspected or confirmed plasma cell malignancies. British Journal of Radiology, 2018, 91, 20180462.	2.2	5
78	Imaging for the diagnosis and response assessment of renal tumours. World Journal of Urology, 2018, 36, 1927-1942.	2.2	59
79	Imaging biomarkers in oncology: Basics and application to MRI. Journal of Magnetic Resonance Imaging, 2018, 48, 13-26.	3.4	39
80	IntAct: intraoperative fluorescence angiography to prevent anastomotic leak in rectal cancer surgery: a randomized controlled trial. Colorectal Disease, 2018, 20, O226-O234.	1.4	83
81	Is there a role for perfusion imaging in assessing treatment response following ablative therapy of small renal masses? A systematic review. European Journal of Radiology Open, 2018, 5, 102-107.	1.6	0
82	Perfusion CT: Technical Aspects. Medical Radiology, 2017, , 121-129.	0.1	0
83	Post Brexit: challenges and opportunities for radiology beyond the European Union. British Journal of Radiology, 2017, 90, 20160852.	2.2	2
84	Primary Rectal Cancer: Repeatability of Global and Local-Regional MR Imaging Texture Features. Radiology, 2017, 284, 552-561.	7.3	66
85	Magnetic Resonance Imaging (MRI) of Intratumoral Voxel Heterogeneity as a Potential Response Biomarker: Assessment in a HER2+ Esophageal Adenocarcinoma Xenograft Following Trastuzumab and/or Cisplatin Therapy. Translational Oncology, 2017, 10, 459-467.	3.7	2
86	Evaluation of treatment response and resistance in metastatic renal cell cancer (mRCC) using integrated 18F-fluorodeoxyglucose (18F-FDG) positron emission tomography/magnetic resonance imaging (PET/MRI); The REMAP study. BMC Cancer, 2017, 17, 392.	2.6	14
87	The effect of post-injection 18F-FDG PET scanning time on texture analysis of peripheral nerve sheath tumours in neurofibromatosis-1. EJNMMI Research, 2017, 7, 35.	2.5	16
88	Streamlining staging of lung and colorectal cancer with whole body MRI; study protocols for two multicentre, non-randomised, single-arm, prospective diagnostic accuracy studies (Streamline C and Tj ETQq0 0 0 0 BT / Overclock 10		
89	Characterisation of malignant peripheral nerve sheath tumours in neurofibromatosis-1 using heterogeneity analysis of 18F-FDG PET. European Journal of Nuclear Medicine and Molecular Imaging, 2017, 44, 1845-1852.	6.4	21
90	P1.03-024 Accuracy of Combined Semantic and Computational CT Features in Predicting Non-Small Cell Lung Cancer Subtype. Journal of Thoracic Oncology, 2017, 12, S556-S557.	1.1	0

#	ARTICLE	IF	CITATIONS
91	Biomarkers in anal cancer: from biological understanding to stratified treatment. British Journal of Cancer, 2017, 116, 156-162.	6.4	46
92	PET/MRIâ€”knocking on the doors of the rich and famous. British Journal of Radiology, 2017, 90, 20170347.	2.2	7
93	Association of Coloproctology of Great Britain & Ireland (<scp>ACPGBI</scp>): Guidelines for the Management of Cancer of the Colon, Rectum and Anus (2017) â€” Multidisciplinary Management. Colorectal Disease, 2017, 19, 37-66.	1.4	77
94	Association of Coloproctology of Great Britain & Ireland (<scp>ACPGBI</scp>): Guidelines for the Management of Cancer of the Colon, Rectum and Anus (2017) â€” Anal Cancer. Colorectal Disease, 2017, 19, 82-97.	1.4	45
95	Guidelines for the use of imaging in the management of patients with myeloma. British Journal of Haematology, 2017, 178, 380-393.	2.5	101
96	Adaptive statistical iterative reconstruction improves image quality without affecting perfusion CT quantitation in primary colorectal cancer. European Journal of Radiology Open, 2017, 4, 69-74.	1.6	7
97	Imaging biomarker roadmap for cancer studies. Nature Reviews Clinical Oncology, 2017, 14, 169-186.	27.6	792
98	The effects of segmentation algorithms on the measurement of 18F-FDG PET texture parameters in non-small cell lung cancer. EJNMMI Research, 2017, 7, 60.	2.5	50
99	Challenges in imaging assessment following liver stereotactic body radiotherapy: pitfalls to avoid in clinical practice. Chinese Clinical Oncology, 2017, 6, S11-S11.	1.2	10
100	An Incidental Renal Oncocytoma: 18F-Choline PET/MRI. Diagnostics, 2016, 6, 14.	2.6	0
101	Molecular and Functional Imaging of Bone Metastases in Breast and Prostate Cancers. Clinical Nuclear Medicine, 2016, 41, e44-e50.	1.3	30
102	Imaging Heterogeneity in Lung Cancer: Techniques, Applications, and Challenges. American Journal of Roentgenology, 2016, 207, 534-543.	2.2	121
103	Imaging Bone Metastases in Breast Cancer: Staging and Response Assessment. Journal of Nuclear Medicine, 2016, 57, 27S-33S.	5.0	84
104	The role of new PET tracers for lung cancer. Lung Cancer, 2016, 94, 7-14.	2.0	47
105	Positron Emission Tomography/Magnetic Resonance Imaging of Gastrointestinal Cancers. Seminars in Ultrasound, CT and MRI, 2016, 37, 352-357.	1.5	4
106	Clinical significance of hypoxia in nasopharyngeal carcinoma with a focus on existing and novel hypoxia molecular imaging. Chinese Clinical Oncology, 2016, 5, 24-24.	1.2	4
107	Pathological heterogeneity after trastuzumab and combination chemotherapy in HER2+ gastroesophageal adenocarcinoma xenograft.. Journal of Clinical Oncology, 2016, 34, 42-42.	1.6	0
108	Water-fat separation in diffusion-weighted EPI using an IDEAL approach with image navigator. Magnetic Resonance in Medicine, 2015, 73, 964-972.	3.0	15

#	ARTICLE	IF	CITATIONS
109	Imaging Tumor Response and Tumoral Heterogeneity in Non-Small Cell Lung Cancer Treated With Antiangiogenic Therapy. <i>Journal of Thoracic Imaging</i> , 2015, 30, 300-307.	1.5	12
110	PET/MRI in Oncological Imaging: State of the Art. <i>Diagnostics</i> , 2015, 5, 333-357.	2.6	37
111	Predicting Response to Neoadjuvant Chemotherapy with PET Imaging Using Convolutional Neural Networks. <i>PLoS ONE</i> , 2015, 10, e0137036.	2.5	139
112	The precision of textural analysis in 18F-FDG-PET scans of oesophageal cancer. <i>European Radiology</i> , 2015, 25, 2805-2812.	4.5	66
113	Non-Small Cell Lung Cancer Treated with Erlotinib: Heterogeneity of ¹⁸ F-FDG Uptake at PET-Association with Treatment Response and Prognosis. <i>Radiology</i> , 2015, 276, 883-893.	7.3	147
114	Molecular imaging of hypoxia in non-small-cell lung cancer. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2015, 42, 956-976.	6.4	50
115	Bench to bedside molecular functional imaging in translational cancer medicine: to image or to imagine?. <i>Clinical Radiology</i> , 2015, 70, 1060-1082.	1.1	54
116	Texture analysis of 125I-A5B7 anti-CEA antibody SPECT differentiates metastatic colorectal cancer model phenotypes and anti-vascular therapy response. <i>British Journal of Cancer</i> , 2015, 112, 1882-1887.	6.4	19
117	Perfusion CT imaging of treatment response in oncology. <i>European Journal of Radiology</i> , 2015, 84, 2380-2385.	2.6	46
118	Imaging body composition in cancer patients: visceral obesity, sarcopenia and sarcopenic obesity may impact on clinical outcome. <i>Insights Into Imaging</i> , 2015, 6, 489-497.	3.4	149
119	Assessment of changes in tumor heterogeneity following neoadjuvant chemotherapy in primary esophageal cancer. <i>Ecological Management and Restoration</i> , 2015, 28, 172-179.	0.4	77
120	Bone metastases in prostate cancer: which scan?. <i>BJU International</i> , 2014, 114, 792-793.	2.5	0
121	Automatic region-of-interest segmentation and registration of dynamic contrast-enhanced images of colorectal tumors. <i>Physics in Medicine and Biology</i> , 2014, 59, 7361-7381.	3.0	3
122	Primary Esophageal Cancer: Heterogeneity as Potential Prognostic Biomarker in Patients Treated with Definitive Chemotherapy and Radiation Therapy. <i>Radiology</i> , 2014, 270, 141-148.	7.3	184
123	Changes in Primary Breast Cancer Heterogeneity May Augment Midtreatment MR Imaging Assessment of Response to Neoadjuvant Chemotherapy. <i>Radiology</i> , 2014, 272, 100-112.	7.3	113
124	Hidradenitis Suppurativa. <i>Diseases of the Colon and Rectum</i> , 2014, 57, 762-771.	1.3	35
125	Imaging Assessment of Lung Tumor Angiogenesis: Insights and Innovations. <i>Seminars in Respiratory and Critical Care Medicine</i> , 2014, 35, 112-128.	2.1	2
126	Still a long way to go to achieve multidisciplinary for the benefit of patients: commentary on the ESMO position paper (<i>Annals of Oncology</i> 25(1): 9-15, 2014). <i>Annals of Oncology</i> , 2014, 25, 1863-1865.	1.2	5

#	ARTICLE	IF	CITATIONS
127	The association of 18F-FDG PET/CT parameters with survival in malignant pleural mesothelioma. European Journal of Nuclear Medicine and Molecular Imaging, 2014, 41, 276-282.	6.4	59
128	Rectal tumour volume (CTV) delineation using T2-weighted and diffusion-weighted MRI: Implications for radiotherapy planning. European Journal of Radiology, 2014, 83, 768-772.	2.6	28
129	Assessment of sarcopenia and changes in body composition after neoadjuvant chemotherapy and associations with clinical outcomes in oesophageal cancer. European Radiology, 2014, 24, 998-1005.	4.5	181
130	MRI of anal cancer: assessing response to definitive chemoradiotherapy. Abdominal Imaging, 2014, 39, 2-17.	2.0	23
131	Quality control within the multicentre perfusion CT study of primary colorectal cancer (PROSPeCT): results of an iodine density phantom study. European Radiology, 2014, 24, 2309-2318.	4.5	4
132	Perfusion CT imaging of colorectal cancer. British Journal of Radiology, 2014, 87, 20130811.	2.2	25
133	Multifunctional Imaging Signature for V-KI-RAS2 Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Mutations in Colorectal Cancer. Journal of Nuclear Medicine, 2014, 55, 386-391.	5.0	74
134	Radiomics in PET: principles and applications. Clinical and Translational Imaging, 2014, 2, 269-276.	2.1	103
135	Anal cancer: ESMOâ€“ESSOâ€“ESTRO clinical practice guidelines for diagnosis, treatment and follow-up. Radiotherapy and Oncology, 2014, 111, 330-339.	0.6	179
136	Perfusion CT: Principles, Technical Aspects and Applications in Oncology. , 2014, , 325-340.		1
137	Correlation of Intra-Tumor 18F-FDG Uptake Heterogeneity Indices with Perfusion CT Derived Parameters in Colorectal Cancer. PLoS ONE, 2014, 9, e99567.	2.5	30
138	How to Select for Preoperative Short-course Radiotherapy, While Considering Long-course Chemoradiotherapy or Immediate Surgery, and Who Benefits?. European Oncology and Haematology, 2014, 10, 17.	0.0	6
139	Assessment of tumoral heterogeneity in NSCLC treated with bevacizumab: A prospective study.. Journal of Clinical Oncology, 2014, 32, e19124-e19124.	1.6	0
140	Changes in tumour vessel density upon treatment with anti-angiogenic agents: relationship with response and resistance to therapy. British Journal of Cancer, 2013, 109, 1230-1242.	6.4	42
141	Functional Imaging of the Liver. Seminars in Ultrasound, CT and MRI, 2013, 34, 54-65.	1.5	13
142	Critical research gaps and translational priorities for the successful prevention and treatment of breast cancer. Breast Cancer Research, 2013, 15, R92.	5.0	320
143	The Role of Hepatocyte-Specific Contrast Agents in Hepatobiliary Magnetic Resonance Imaging. Seminars in Ultrasound, CT and MRI, 2013, 34, 44-53.	1.5	23
144	Quantifying tumour heterogeneity in 18F-FDG PET/CT imaging by texture analysis. European Journal of Nuclear Medicine and Molecular Imaging, 2013, 40, 133-140.	6.4	395

#	ARTICLE	IF	CITATIONS
145	CT Perfusion in Oncologic Imaging: A Useful Tool?. American Journal of Roentgenology, 2013, 200, 8-19.	2.2	146
146	Assessment of tumor heterogeneity by CT texture analysis: Can the largest cross-sectional area be used as an alternative to whole tumor analysis?. European Journal of Radiology, 2013, 82, 342-348.	2.6	323
147	Functional imaging of the bowel. Abdominal Imaging, 2013, 38, 1203-1213.	2.0	2
148	Reproducibility of Dynamic Contrast-enhanced MR Imaging: Why We Should Care. Radiology, 2013, 266, 698-700.	7.3	18
149	Primary Colorectal Cancer: Use of Kinetic Modeling of Dynamic Contrast-enhanced CT Data to Predict Clinical Outcome. Radiology, 2013, 267, 145-154.	7.3	25
150	Assessment of Primary Colorectal Cancer Heterogeneity by Using Whole-Tumor Texture Analysis: Contrast-enhanced CT Texture as a Biomarker of 5-year Survival. Radiology, 2013, 266, 177-184.	7.3	384
151	Are Pretreatment ¹⁸ F-FDG PET Tumor Textural Features in Non-Small Cell Lung Cancer Associated with Response and Survival After Chemoradiotherapy?. Journal of Nuclear Medicine, 2013, 54, 19-26.	5.0	361
152	Non-Small Cell Lung Cancer: Histopathologic Correlates for Texture Parameters at CT. Radiology, 2013, 266, 326-336.	7.3	384
153	Fluorodeoxyglucose positron emission tomography (¹⁸ F-FDG PET)/computed tomography (CT) in bladder cancer. BJU International, 2013, 112, 709-709.	2.5	1
154	Body composition and association with treatment toxicity in patients with advanced renal cell carcinoma receiving targeted agents.. Journal of Clinical Oncology, 2013, 31, e15608-e15608.	1.6	0
155	Imaging assessment of desmoid tumours in familial adenomatous polyposis: is state-of-the-art 1.5 T MRI better than 64-MDCT?. British Journal of Radiology, 2012, 85, e254-e261.	2.2	29
156	The Flow-Metabolic Phenotype of Primary Colorectal Cancer: Assessment by Integrated ¹⁸ F-FDG PET/Perfusion CT with Histopathologic Correlation. Journal of Nuclear Medicine, 2012, 53, 687-692.	5.0	29
157	Phase Ib trial of radiotherapy in combination with combretastatin-A4-phosphate in patients with non-small-cell lung cancer, prostate adenocarcinoma, and squamous cell carcinoma of the head and neck. Annals of Oncology, 2012, 23, 231-237.	1.2	68
158	Integrated ¹⁸ F-FDG PET/CT and Perfusion CT of Primary Colorectal Cancer: Effect of Inter- and Intraobserver Agreement on Metabolic-Vascular Parameters. American Journal of Roentgenology, 2012, 199, 1003-1009.	2.2	15
159	Operable Non-Small Cell Lung Cancer: Correlation of Volumetric Helical Dynamic Contrast-enhanced CT Parameters with Immunohistochemical Markers of Tumor Hypoxia. Radiology, 2012, 264, 581-589.	7.3	47
160	Can Combined ¹⁸ F-FDG-PET and Dynamic Contrast-Enhanced MRI Predict Behavior of Desmoid Tumors in Patients With Familial Adenomatous Polyposis?. Diseases of the Colon and Rectum, 2012, 55, 1032-1037.	1.3	10
161	Functional Computed Tomography Imaging. Investigative Radiology, 2012, 47, 1.	6.2	4
162	Computed Tomography Perfusion Imaging for Therapeutic Assessment. Investigative Radiology, 2012, 47, 2-4.	6.2	39

#	ARTICLE	IF	CITATIONS
163	Predicting response to neoadjuvant chemotherapy in primary breast cancer using volumetric helical perfusion computed tomography: a preliminary study. <i>European Radiology</i> , 2012, 22, 1871-1880.	4.5	10
164	Perfusion CT assessment of the colon and rectum: Feasibility of quantification of bowel wall perfusion and vascularization. <i>European Journal of Radiology</i> , 2012, 81, 821-824.	2.6	18
165	Diffusion tensor imaging (DTI) of desmoid tumours in familial adenomatous polyposis: Initial experience. <i>European Journal of Radiology</i> , 2012, 81, 3646-3651.	2.6	3
166	Assessment of tumor heterogeneity: an emerging imaging tool for clinical practice?. <i>Insights Into Imaging</i> , 2012, 3, 573-589.	3.4	738
167	Reproducibility of 2D and 3D Fractal Analysis Techniques for the Assessment of Spatial Heterogeneity of Regional Blood Flow in Rectal Cancer. <i>Radiology</i> , 2012, 263, 865-873.	7.3	36
168	Diffusion tensor imaging of the anal canal at 3 tesla: Feasibility and reproducibility of anisotropy measures. <i>Journal of Magnetic Resonance Imaging</i> , 2012, 35, 820-826.	3.4	14
169	Current status and guidelines for the assessment of tumour vascular support with dynamic contrast-enhanced computed tomography. <i>European Radiology</i> , 2012, 22, 1430-1441.	4.5	180
170	Assessment of the metabolic flow phenotype of primary colorectal cancer: correlations with microvessel density are influenced by the histological scoring method. <i>European Radiology</i> , 2012, 22, 1687-1692.	4.5	14
171	Novel Oncologic Drugs: What They Do and How They Affect Images. <i>Radiographics</i> , 2011, 31, 2059-2091.	3.3	71
172	Commercial software upgrades may significantly alter Perfusion CT parameter values in colorectal cancer. <i>European Radiology</i> , 2011, 21, 744-749.	4.5	33
173	Radiation dose from volumetric helical perfusion CT of the thorax, abdomen or pelvis. <i>European Radiology</i> , 2011, 21, 974-981.	4.5	44
174	Assessment of Response to Tyrosine Kinase Inhibitors in Metastatic Renal Cell Cancer: CT Texture as a Predictive Biomarker. <i>Radiology</i> , 2011, 261, 165-171.	7.3	328
175	Investigating Vulnerable Atheroma Using Combined ¹⁸ F-FDG PET/CT Angiography of Carotid Plaque with Immunohistochemical Validation. <i>Journal of Nuclear Medicine</i> , 2011, 52, 1698-1703.	5.0	69
176	Angiogenesis in Non-small Cell Lung Cancer. <i>Journal of Thoracic Imaging</i> , 2010, 25, 142-150.	1.5	23
177	Reply to letter to the editor: Assessment of the spatial pattern of colorectal tumour perfusion estimated at perfusion CT using two-dimensional fractal analysis. <i>European Radiology</i> , 2010, 20, 120-120.	4.5	0
178	Magnetic Resonance Imaging Assessment of Squamous Cell Carcinoma of the Anal Canal Before and After Chemoradiation: Can MRI Predict for Eventual Clinical Outcome?. <i>International Journal of Radiation Oncology Biology Physics</i> , 2010, 78, 715-721.	0.8	62
179	The Role of Functional Imaging in Colorectal Cancer. <i>American Journal of Roentgenology</i> , 2010, 195, 54-66.	2.2	56
180	CT response assessment combining reduction in both size and arterial phase density correlates with time to progression in metastatic renal cancer patients treated with targeted therapies. <i>Cancer Biology and Therapy</i> , 2010, 9, 15-19.	3.4	108

#	ARTICLE	IF	CITATIONS
181	Quantitative helical dynamic contrast enhanced computed tomography assessment of the spatial variation in whole tumour blood volume with radiotherapy in lung cancer. Lung Cancer, 2010, 69, 71-76.	2.0	16
182	Dynamic Contrast-Enhanced and Diffusion-Weighted MRI of the Gastrointestinal Tract. Medical Radiology, 2010, , 51-63.	0.1	1
183	Imaging for staging and response assessment in rectal cancer. Current Colorectal Cancer Reports, 2009, 5, 224-231.	0.5	0
184	Can perfusion CT assessment of primary colorectal adenocarcinoma blood flow at staging predict for subsequent metastatic disease? A pilot study. European Radiology, 2009, 19, 79-89.	4.5	82
185	Assessment of the spatial pattern of colorectal tumour perfusion estimated at perfusion CT using two-dimensional fractal analysis. European Radiology, 2009, 19, 1358-1365.	4.5	59
186	Effect of intravenous contrast agent volume on colorectal cancer vascular parameters as measured by perfusion computed tomography. Clinical Radiology, 2009, 64, 368-372.	1.1	11
187	Functional Imaging of Colorectal Cancer: Positron Emission Tomography, Magnetic Resonance Imaging, and Computed Tomography. Clinical Colorectal Cancer, 2009, 8, 77-87.	2.3	18
188	Quantitative Assessment of Colorectal Cancer Perfusion: Perfusion Computed Tomography and Dynamic Contrast Enhanced Magnetic Resonance Imaging. , 2009, , 183-205.		0
189	Functional imaging of colorectal cancer: positron emission tomography, magnetic resonance imaging, and computed tomography. Clinical Colorectal Cancer, 2009, 8, 77-87.	2.3	0
190	CT coronary angiography: Quantitative assessment of myocardial perfusion using test bolus dataâ€‘initial experience. European Radiology, 2008, 18, 2155-2163.	4.5	20
191	Quantitative Assessment of Colorectal Cancer Tumor Vascular Parameters by Using Perfusion CT: Influence of Tumor Region of Interest. Radiology, 2008, 247, 726-732.	7.3	81
192	Colorectal Tumor Vascularity: Quantitative Assessment with Multidetector CTâ€‘Do Tumor Perfusion Measurements Reflect Angiogenesis?. Radiology, 2008, 249, 510-517.	7.3	128
193	Effect of Temporal Interval Between Scan Acquisitions on Quantitative Vascular Parameters in Colorectal Cancer: Implications for Helical Volumetric Perfusion CT Techniques. American Journal of Roentgenology, 2008, 191, W288-W292.	2.2	35
194	Differentiation between Diverticulitis and Colorectal Cancer: Quantitative CT Perfusion Measurements versus Morphologic Criteriaâ€‘Initial Experience. Radiology, 2007, 242, 456-462.	7.3	120
195	Leukocyte DNA Damage after Multiâ€‘Detector Row CT: A Quantitative Biomarker of Low-Level Radiation Exposure. Radiology, 2007, 242, 244-251.	7.3	208
196	Quantitative Tumor Perfusion Assessment with Multidetector CT: Are Measurements from Two Commercial Software Packages Interchangeable?. Radiology, 2007, 242, 777-782.	7.3	120
197	Effect of nitric-oxide synthesis on tumour blood volume and vascular activity: a phase I study. Lancet Oncology, The, 2007, 8, 111-118.	10.7	105
198	Functional imaging of colorectal cancer angiogenesis. Lancet Oncology, The, 2007, 8, 245-255.	10.7	92

#	ARTICLE	IF	CITATIONS
199	Acute tumor vascular effects following fractionated radiotherapy in human lung cancer: In vivo whole tumor assessment using volumetric perfusion computed tomography. International Journal of Radiation Oncology Biology Physics, 2007, 67, 417-424.	0.8	78
200	Tumor Antivascular Effects of Radiotherapy Combined with Combretastatin A4 Phosphate in Human Nonâ€“Small-Cell Lung Cancer. International Journal of Radiation Oncology Biology Physics, 2007, 67, 1375-1380.	0.8	73
201	Imaging tumor angiogenesis: functional assessment using MDCT or MRI?. Abdominal Imaging, 2006, 31, 194-199.	2.0	70
202	Polyp Detection with CT Colonography: Primary 3D Endoluminal Analysis versus Primary 2D Transverse Analysis with Computer-assisted Reader Software. Radiology, 2006, 239, 759-767.	7.3	53
203	Quantitative Assessment of Tissue Perfusion Using MDCT: Comparison of Colorectal Cancer and Skeletal Muscle Measurement Reproducibility. American Journal of Roentgenology, 2006, 187, 164-169.	2.2	70
204	Quantitative Assessment of Lung Cancer Perfusion Using MDCT: Does Measurement Reproducibility Improve with Greater Tumor Volume Coverage?. American Journal of Roentgenology, 2006, 187, 1079-1084.	2.2	72
205	Quantitative colorectal cancer perfusion measurement by multidetector-row CT: does greater tumour coverage improve measurement reproducibility?. British Journal of Radiology, 2006, 79, 578-583.	2.2	28
206	Lung Cancer Perfusion at Multiâ€“Detector Row CT: Reproducibility of Whole Tumor Quantitative Measurements. Radiology, 2006, 239, 547-553.	7.3	132
207	Quantitative Colorectal Cancer Perfusion Measurement Using Dynamic Contrast-Enhanced Multidetector-Row Computed Tomography. Journal of Computer Assisted Tomography, 2005, 29, 59-63.	0.9	65
208	Imaging breast cancer response during neoadjuvant systemic therapy. Expert Review of Anticancer Therapy, 2005, 5, 893-905.	2.4	23
209	Quantitative Assessment of Colorectal Cancer Perfusion Using MDCT: Inter- and Intraobserver Agreement. American Journal of Roentgenology, 2005, 185, 225-231.	2.2	68
210	Is direct radiologist supervision of abdominal computed tomography (CT) scans necessary?. Clinical Radiology, 2005, 60, 758-761.	1.1	2
211	Local radiological staging of rectal cancer. Clinical Radiology, 2004, 59, 215-226.	1.1	40
212	Optimizing Bowel Preparation for Multidetector Row CT Colonography: Effect of Citramag and Picolax. Clinical Radiology, 2003, 58, 723-732.	1.1	29
213	Optimizing Colonic Distention for Multiâ€“Detector Row CT Colonography: Effect of Hyoscine Butylbromide and Rectal Balloon Catheter. Radiology, 2003, 229, 99-108.	7.3	164
214	The Therapeutic Impact of Abdominal Ultrasound in Patients with Acute Abdominal Symptoms. Clinical Radiology, 2002, 57, 268-271.	1.1	42
215	Dynamic MR Imaging of the Pelvic Floor in Asymptomatic Subjects. American Journal of Roentgenology, 2000, 174, 661-666.	2.2	141
216	Editorial Comment: Artificial Intelligence for Lung Nodulesâ€“Progress, But Is It Enough?. American Journal of Roentgenology, 0, , .	2.2	0